Dailypharm Live Search Close

Adtralza becomes the 2nd reimbursed biological drug for AD

By Son, Hyung-Min | translator Kang, Shin-Kook

24.05.31 05:10:00

가나다라 0
Was reimbursed from May 1st …can be used in patients aged 12 years or older

Becomes 2nd biological treatment option for AD following Dupixent…broadens choice

 ▲Jiyoung Ahn, Professor of Dermatology at the National Medical Center


LEO Pharma Korea has launched Adtralza (tralokinumab) as the 2nd biologic drug in the atopic dermatitis market and is on its way to take on Dupixent.

LEO Pharma has been emphasizing that Adtralza has a longer dosing interval after 16 weeks compared to existing therapies and is relatively cheaper, reducing the cost burden for patients.

On March 30, LEO Pharma held a press conference at the Grand Hyatt Hotel in Seoul to celebrate the reimbursed launch of Adtralza. Adtralza is a biological drug that selectively targets interleukin-13 (IL-13). The drug is being reimbursed for the treatment of chronic severe atopic dermatitis in adults and adolescents from the 1st of this month.

Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)